SOLENO THERAPEUTICS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SOLENO THERAPEUTICS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $1.45M | Mar 15, 2017 |
| FY2016 | Dec 31, 2015 | $607.5K | Mar 15, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $3.00M | Mar 13, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($58.5K) | Mar 15, 2017 |
| FY2016 | Dec 31, 2015 | $254.8K | Mar 15, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 25, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.89M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($175.85M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($38.99M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($24.07M) | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | ($30.91M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($24.64M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($30.77M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($13.34M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($15.39M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($12.07M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.41M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($187.67M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($41.38M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($24.40M) | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | ($31.53M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($36.29M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($23.49M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($14.30M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($12.17M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($8.32M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.63M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $78.57M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $25.19M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $15.27M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $21.45M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $23.19M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $16.27M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $7.18M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $3.07M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $2.25M | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.13M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $105.86M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $13.48M | Feb 25, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.80M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($69.10M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($24.94M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($20.78M) | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | ($27.77M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($25.22M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($17.38M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($11.68M) | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | ($9.95M) | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | ($13.50M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $218.0K | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $13.0K | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $22.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $7.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $21.0K | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $8.0K | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $2.0K | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $14.8K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $563.83M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $330.97M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $180.69M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $26.50M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $35.55M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $64.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $38.17M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $43.15M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $39.02M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $5.56M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $113.72M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $85.86M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $23.18M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $16.15M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $17.76M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $19.44M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $23.23M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $12.74M | Mar 4, 2020 |
| FY2018 | Jun 30, 2018 | $16.70M | Mar 20, 2019 |
| FY2018 | Mar 31, 2018 | $13.08M | Mar 20, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $450.12M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $245.11M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $157.51M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $10.35M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $17.79M | Feb 28, 2025 |
| FY2022 | Dec 31, 2020 | $45.55M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | $14.95M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $30.41M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $26.82M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $3.44M | Mar 20, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $817.5K | Mar 15, 2017 |
| FY2016 | Dec 31, 2015 | $916.8K | Mar 15, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 25, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($431.37M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($452.26M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($276.41M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($237.42M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($213.36M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($182.45M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($157.81M) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | ($127.03M) | Mar 4, 2020 |
| FY2018 | Jun 30, 2018 | ($124.56M) | Mar 20, 2019 |
| FY2018 | Mar 31, 2018 | ($117.50M) | Mar 20, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.11M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $87.93M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $169.68M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $14.60M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $21.30M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $49.22M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $20.73M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $23.10M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $17.10M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | $2.73M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | (5) | Mar 22, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | (5) | Mar 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.29M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 45.70M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 31.68M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 8.16M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 5.32M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 79.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 44.66M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 31.76M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 19.24M | Mar 20, 2019 |
| FY2017 | Dec 31, 2016 | 3.36M | Apr 2, 2018 |